A Phase 3,6-Month, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Two Doses of Asoprisnil Versus Placebo in Subjects With Uterine Leiomyomata [uterine leiomyoma]

Trial Profile

A Phase 3,6-Month, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Two Doses of Asoprisnil Versus Placebo in Subjects With Uterine Leiomyomata [uterine leiomyoma]

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2008

At a glance

  • Drugs Asoprisnil (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors TAP Pharmaceuticals
  • Most Recent Events

    • 21 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top